Yes, a patient with eGFR 39 mL/min/1.73 m² can take lisinopril and should continue it even at this level of kidney function.
Lisinopril is explicitly safe and recommended for patients with CKD stage 3b (eGFR 30-44 mL/min/1.73 m²), and current guidelines strongly support continuing ACE inhibitors even when eGFR falls below 30 mL/min/1.73 m². 1
Key Clinical Guidance
Dosing at eGFR 39
- No dose adjustment is required at eGFR 39 mL/min/1.73 m² 2
- The FDA label specifies that dose reduction is only needed when creatinine clearance drops to ≤30 mL/min 2
- At eGFR >30 mL/min, use standard dosing: start at 5-10 mg daily for hypertension, titrate to 20-40 mg as needed 2
When to Consider Lisinopril Based on Albuminuria Status
The 2024 KDIGO guidelines provide clear indications 1:
Strong recommendations (Grade 1B):
- With diabetes + moderate-to-severe albuminuria (A2-A3): Start ACE inhibitor
- Without diabetes + severe albuminuria (A3): Start ACE inhibitor
Weaker recommendation (Grade 2C):
- Without diabetes + moderate albuminuria (A2): Consider ACE inhibitor
Other indications at any albuminuria level:
- Hypertension requiring treatment
- Heart failure with reduced ejection fraction
Critical Monitoring Protocol
After starting or increasing lisinopril dose 1:
Check within 2-4 weeks:
- Serum creatinine/eGFR
- Serum potassium
- Blood pressure
Acceptable changes:
- Continue therapy if creatinine rises ≤30% from baseline 1
- Hyperkalemia can often be managed with potassium-lowering measures rather than stopping the drug 1
Stop or reduce dose only if:
- Creatinine rises >30% within 4 weeks 1
- Symptomatic hypotension occurs 1
- Uncontrolled hyperkalemia despite medical management 1
Important Clinical Nuances
The eGFR <30 Threshold Is NOT a Contraindication
A critical practice point: Continue ACE inhibitors even when eGFR falls below 30 mL/min/1.73 m² 1. This represents a paradigm shift from older teaching. The only consideration for discontinuation is when eGFR drops to <15 mL/min/1.73 m² to reduce uremic symptoms 1.
Hyperkalemia Risk Management
Research shows hyperkalemia risk increases with declining kidney function, but this is manageable 3:
- At eGFR 30-60 mL/min, the 90-day hyperkalemia risk is approximately 2-3% 3
- Risk factors include: diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and high-dose ACE inhibitors 3
- Do not reflexively stop the ACE inhibitor for mild hyperkalemia—use dietary modification, diuretics, or potassium binders first 1
Real-World Evidence Supports Safety
Multiple studies demonstrate lisinopril's safety and efficacy in patients with impaired renal function 4, 5, 6, 7:
- Effective blood pressure control achieved with median doses of 10 mg daily
- GFR remained stable during treatment in most patients
- Well-tolerated with appropriate dose adjustments
Common Pitfall to Avoid
Do not withhold or discontinue ACE inhibitors solely based on eGFR values above 30 mL/min. The renoprotective and cardiovascular benefits outweigh risks when properly monitored. The initial small decline in eGFR after starting therapy is expected and hemodynamically mediated—it does not represent kidney injury 1.
Practical Algorithm
- At eGFR 39: Start standard dose (5-10 mg daily), no adjustment needed
- Monitor at 2-4 weeks: Check creatinine, potassium, BP
- If creatinine rises ≤30%: Continue therapy, this is acceptable
- If creatinine rises >30%: Consider dose reduction or temporary hold
- If hyperkalemia develops: Manage with dietary changes, diuretics, or binders before stopping drug
- Titrate to target dose: Use highest tolerated dose for maximum benefit 1